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Abstract
We investigated the relationship between gut health, visceral fat dysfunction and metabolic disorders in diet-induced
obesity. C57BL/6J mice were fed control or high saturated fat diet (HFD). Circulating glucose, insulin and inflammatory
markers were measured. Proximal colon barrier function was assessed by measuring transepithelial resistance and mRNA
expression of tight-junction proteins. Gut microbiota profile was determined by 16S rDNA pyrosequencing. Tumor necrosis
factor (TNF)-a and interleukin (IL)-6 mRNA levels were measured in proximal colon, adipose tissue and liver using RT-qPCR.
Adipose macrophage infiltration (F4/80
+) was assessed using immunohistochemical staining. HFD mice had a higher insulin/
glucose ratio (P=0.020) and serum levels of serum amyloid A3 (131%; P=0.008) but reduced circulating adiponectin (64%;
P=0.011). In proximal colon of HFD mice compared to mice fed the control diet, transepithelial resistance and mRNA
expression of zona occludens 1 were reduced by 38% (P,0.001) and 40% (P=0.025) respectively and TNF-a mRNA level was
6.6-fold higher (P=0.037). HFD reduced Lactobacillus (75%; P,0.001) but increased Oscillibacter (279%; P=0.004) in fecal
microbiota. Correlations were found between abundances of Lactobacillus (r=0.52; P=0.013) and Oscillibacter (r=20.55;
P=0.007) with transepithelial resistance of the proximal colon. HFD increased macrophage infiltration (58%; P=0.020), TNF-a
(2.5-fold, P,0.001) and IL-6 mRNA levels (2.5-fold; P=0.008) in mesenteric fat. Increased macrophage infiltration in epididymal
fat was also observed with HFD feeding (71%; P=0.006) but neither TNF-a nor IL-6 was altered. Perirenal and subcutaneous
adipose tissue showed no signs of inflammation in HFD mice. The current results implicate gut dysfunction, and attendant
inflammation of contiguous adipose, as salient features of the metabolic dysregulation of diet-induced obesity.
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Introduction
Visceral adiposity is strongly related to metabolic dysfunction
including insulin resistance and systemic inflammation [1–3]. The
deleterious metabolic effect of visceral fat is a consequence, in
large part, of increased production of pro-inflammatory cytokines
[4]. Adipose-derived immune factors primarily originate from cells
in the stromal-vascular fraction of fat depots [5,6]. Specifically,
macrophage infiltration has been identified as a major determi-
nant of the metabolic effect of adipose tissue. The abundance of
macrophages in visceral fat was negatively correlated with insulin
sensitivity of obese individuals, whereas no such relationship was
observed with subcutaneous fat [7]. The primary driver of the
macrophage infiltration and pro-inflammatory profile of visceral
fat, however, remains largely unknown.
Evidence is now persuasive that the gut may play an important
role in inducing adipose inflammation and metabolic disorders. In
patients with Crohn’s disease, the inflamed gut is associated with
an expanded mesenteric fat depot characterized by an increased
infiltration of immune cells [8]. A causal relationship between gut
inflammation and mesenteric fat dysfunction (notably a relative
expansion in size and an increase in expression of macrophages
and immune factors) has been demonstrated in animal models of
experimental colitis [9,10]. Impaired gut barrier function, along
with gut inflammation, have also been observed in both genetic
[11] and dietary [12,13] models of obesity.
Finally, there is an emerging body of literature demonstrating
an association between altered gut microbiota profile and obesity
in humans (see [14] and [15] for a recent review) which, from
pioneering work on rodents [12,16,17], appears to be causative.
The cross-linkage between gut microbiota, metabolic dysfunction
and the immune system is best illustrated in Toll-like receptor-5
knockout mice which develop spontaneous colitis, insulin resis-
tance, hyperlipidemia and increased visceral fat deposition [18].
Importantly, all of these deleterious effects can be ameliorated by
antibiotic administration, implicating gut microbiota change as
causative and suggesting a feedback loop from the innate immune
system to gut inflammation and microbiota profile.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34233Taken together the case can be made, see [19], that obesogenic
diets induce gut dysfunction, which may lead to the stimulation of
contiguous fat by an adverse microbial load and subsequently
results in visceral fat inflammation and systemic metabolic
dysregulation.
The aim of the present study, therefore, was to characterize the
relationship between gut health, visceral fat dysfunction and
metabolic dysregulation in diet-induced obese mice. We showed
that a prolonged high saturated fat feeding induced inflammation
and impaired barrier function in the gut which associated with
specific alterations in microbiota profile. This, together with a
distinct pro-inflammatory nature of the mesenteric fat contiguous
with the gut but not of depots more remote, implicates the gut in
the genesis of visceral adipose inflammation and systemic
metabolic dysfunction.
Methods
Ethics statement
All procedures were approved by the University of Sydney
Animal Ethics Committee (approval number K00/2-2010/3/
5225).
Animals
Female C57BL/6J mice were obtained from the Australian
Animal Resources Centre (Perth, Australia), group-housed (2–4
mice per cage) and kept with regulated temperature (18–22uC) and
humidity (,50%) with a 12 h light/dark cycle. Starting at 16
weeks of age, the mice were fed either a control (10% kcal from fat)
or a high saturated fat diet (HFD; 60% kcal from fat, of which
34% was saturated fat) ad libitum with free access to water for 8 or
12 weeks. For each mouse fresh stools (1 pellet per day) were
collected on 3 consecutive days in the week before termination for
gut microbiota profiling. At termination mice were anesthetized
after a 4 h fast. Blood was taken by heart puncture and serum was
stored at 280uC. After flushing with ice-cold bicarbonate buffer
[20], segments of proximal colon (immediately below the cecum)
were taken for assessment of gut permeability and gene expression
(see below). Mesenteric, epididymal, perirenal and subcutaneous
fat samples were taken for immunohistochemical staining and
gene expression analysis, as was liver for the latter measurements.
Biochemical analyses
Blood glucose was measured using a glucometer (Accu-Chek
Performa, Roche, Mannheim, Germany). Serum concentrations of
insulin, adiponectin and serum amyloid A3 were measured using
assays from Millipore (Billerica, MA, USA). Liver was homoge-
nized in isopropanol. Liver triglycerides and serum concentrations
of alanine transaminase and triglycerides were measured using kits
from Horiba ABX (Montpellier, France) and the assays were
performed on the ABX Pentra 400 (Horiba ABX). Serum
concentrations of interleukin (IL)-1b, IL-10, monocyte chemotac-
tic protein (MCP)-1, tumor necrosis factor (TNF)-a, IL-6, IL-
12p40 and plasminogen activator inhibitor (PAI)-1 were deter-
mined using commercially available cytokine kits and the xMAPH
technology (Luminex Corporation, Austin, TX, USA). The data
were analyzed with a four- or five-parametric curve fitting using
the Bio-Plex Manager Software (version 5.0, Life Science
Research, Hercules, CA, USA).
Assessment of gut permeability
Gut permeability was measured as described by Wang et al [21]
with minor modifications. The segments of proximal colon for gut
permeability measurement were opened along the mesenteric
border and mounted in the Ussing chamber with an aperture of
0.3 cm
2. The chamber was connected to a VCC MC6 amplifier,
controlled and monitored using the Acquire & Analyze software
(V2.3.177 Physiologic Instruments, San Diego, CA, USA).
Experiments were carried out under current-clamp (open-circuit)
conditions as described previously [22]. Segments of colon were
incubated in oxygenated (95% O2;5 %C O 2) bicarbonate buffer at
37uC [20]. Tissue was equilibrated for 15 min, thereafter a 3 mA
current pulse was applied across the intestinal wall every 6 sec for
30 min. The transepithelial potential was measured and recorded
by the Acquire & Analyze software, and the change in potential
induced by the current pulse was used to calculate transepithelial
resistance according to Ohm’s Law.
Quantitative real-time PCR
RNA was extracted from homogenized tissue using TRI reagent
(Sigma-Aldrich, St Louis, MO, USA) and isolated by phenol/
chloroform extraction. Total RNA (200 ng) was reverse tran-
scribed to cDNA using BioScript
TM (Bioline, London, UK) and
random hexamers (Applied Biosystems, Carlsbad, CA, USA).
Primer sequences for sterol regulatory element binding protein
(SREBP)-1c [23], peroxisome proliferator-activated receptor
(PPAR)-c [23], proglucagon [24], zona occludens (ZO)-1 [25],
occludin [26] and IL-10 [27] have been published elsewhere.
Primers for SCD1, TNF-a and IL-6 were purchased from Qiagen
(Valencia, CA, USA). mRNA expression was quantified by RT-
qPCR using the Rotorgene
TM 3000 Real Time Thermal Cycler
(Qiagen). Fluorescence data were analyzed using the Rotor-Gene
6 software (version 6.0, Qiagen). mRNA expression was
normalized to RPL-19 [24], UBC [28] and 18S rRNA [29] for
colon, adipose tissue and liver respectively and reported as
arbitrary units.
Immunohistochemical staining
Fat samples were fixed in formalin overnight and embedded in
paraffin. Sections of 10 mm thickness were treated with 10 mg/ml
proteinase K (Sigma-Aldrich) at room temperature for antigen
retrieval. Endogenous peroxidase and biotin signals were mini-
mized using 0.3% (v/v) hydrogen peroxide and avidin/biotin
block (Dako, Glostrup, Denmark) respectively. After incubating
with 10% (v/v) normal horse serum to reduce non-specific
staining, sections were incubated with purified anti-mouse F4/80
antibody (BioLegend, San Diego, CA, USA) for 1 h and
subsequently with biotinylated rabbit anti-rat IgG antibody
(Vector Laboratories, Burlingame, CA, USA) for 30 min at room
temperature. The expression of F4/80 was detected using the
VECTASTAIN
H ABC Kit (Vector Laboratories) and the Liquid
DAB+ Substrate Chromogen System (Dako). All sections were
counterstained with hematoxylin. F4/80
+ cells were quantified by
counting the number of adipocytes and F4/80
+ cells in 10 random
areas at640 magnification and the abundance of F4/80
+ cells was
normalized to 100 adipocytes [30]. Adipocyte size was determined
by averaging the cross-sectional area of 5 adipocytes of each of the
10 selected 640 magnification field using ImageJ (version 1.44p,
National Institutes of Health, MD, USA).
Gut microbiota profiling
For each mouse three stool pellets (one per day) were pooled
and homogenized in TE buffer (pH 7.5). DNA was extracted from
0.5 ml of homogenate using a bead beating method as described
previously [31] and stored at 220uC. Metagenomic DNA
(.500 ng from each mouse) was sent to Research and Testing
Laboratories (Lubbock, USA) for bacterial tag-encoded FLX
amplicon pyrosequencing (bTEFAP) of the V6–V9 region of the
Gut and Mesenteric Fat Dysfunction in Obesity
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GCCCGCAC39) and R1492 (59ATTAGATACCCNGGTAG39)
incorporating domainsfor454sequencingandunique identification
tags were used to allow the identification of sequences from
individual sample. Amplicons were sequenced on a GS Pico Titer
Plate using the Roche 454 FLX instrument with corresponding
FLX titanium reagents (Roche Applied Science, Indianapolis, IN,
USA).
bTEFAP raw data were processed using Mothur [32] unless
stated otherwise. Parameters used to filter sequences for analysis
were based upon published studies [33,34]. Briefly, sequences
from the raw 454 data were quality-filtered to exclude those with
an average Phred score ,30. Remaining sequence reads were
binned into individual sample sets by the unique tags with
sequences .200 nucleotides in length (excluding primers and tags)
retained. The sequences were then screened to remove chimeras
using chimera slayer within Mothur to give a final set of quality-
filtered sequence reads for each sample. Taxonomic classifications
were assigned using the naı ¨ve Bayesian algorithm with the
Ribosomal Database Project (RDP) Training Set 6 as a reference
database. No new data were generated from DNA sequencing.
Nomenclature of all bacterial identification was based on Bergey’s
taxonomic outline. Within each sample the number of sequences
for each bacterial taxonomic assignment is expressed as a
percentage of the total reads retained after quality-filtering
(relative abundance). To quantify the coverage and sampling
effort of bTEFAP, RDP pyrosequencing pipeline was used to
generate rarefaction curves of the sequences.
Statistical analysis
Data are expressed as means 6 SEM. Student’s t-test, one-way
or two-way ANOVA were used to compare data from different
treatment groups. Corrections of p-values for multiple testing were
performed using Bonferroni post hoc tests. Relationships between
selected outcome variables were examined by Pearson’s correla-
tion. Statistical analyses were performed using the GraphPad
Prism Program (version 5.01, GraphPad Software Inc., San Diego,
CA, USA). Significance was accepted at P,0.05.
Results
High saturated fat diet induced weight gain, systemic
insulin resistance and inflammation
By the end of the 8- and 12-week feeding protocols, the body
weights of HFD mice were 22% and 36% higher respectively than
animals fed the control diet (27.360.7 g vs 22.460.5 g for
controls; P,0.001 at 8 weeks and 30.161.1 g vs 22.260.4 g for
controls; P,0.001 at 12 weeks). Eight and 12 week results were not
different for all other outcome variables and were therefore
combined for analyses. HFD mice had a higher insulin/glucose
ratio (1.4-fold; P=0.020; insulin 91.168.8 pmol/l vs 56.86
6.8 pmol/l for controls; glucose 10.960.3 mmol/l vs 9.460.5
mmol/l for controls) as a marker of insulin resistance (Figure 1A).
Circulating levels of the acute phase inflammatory marker serum
amyloid A3 were 2.3-fold (P=0.008; Figure 1B) higher in HFD
mice, but in contrast, those of adiponectin were decreased by 36%
(P=0.011; Figure 1C). Serum concentrations of triglycerides, IL-
1b, IL-10, MCP-1, TNF-a, IL-6, IL-12p40 and PAI-1 were not
different between the diet groups (data not shown).
High saturated fat diet increased gut permeability and
inflammation
In the proximal colon, transepithelial resistance of HFD mice
was reduced by 38% (37.462.6 Ohm.cm
2 vs 60.864.5 Ohm.cm
2
for controls; P,0.001; Figure 2A) as compared to controls. mRNA
expression of ZO-1 and proglucagon were also reduced by 40%
Figure 1. Serum biochemical analyses. Insulin/glucose ratio (A), concentrations of serum amyloid A3 (B) and adiponectin (C) in control and high
saturated fat diet (HFD) fed mice (n=15–16 per group). Data are shown as mean 6 SEM. **P,0.01 and *P,0.05 compared to control.
doi:10.1371/journal.pone.0034233.g001
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(Figure 2B), whereas the mRNA levels of occludin were not
different between the diet groups (data not shown). The colon
tissue of the HFD treatment group had increased mRNA
expression of TNF-a by 6.6-fold (P=0.037) but that of IL-6 was
unchanged (Figure 3).
High saturated fat diet altered gut microbiota profile
After quality-filtering a total of 246,694 sequences were
obtained from 16 control and 16 HFD mice with a mean of
7,709 sequences per mouse (range 1,758–15,005; Table S1). The
average number of reads for the control diet sample series was
higher than that from HFD, however rarefaction analysis showed
that taxonomic richness had plateaued in all samples at higher
taxon level. Rarefaction curves at 95% sequence identity,
considered to approximate genus level, showed that the rate of
sampling was comparable across all samples and demonstrated
sampling depth at this taxonomic resolution was comparable to
previously reported studies (Figure S1) [35–37]. At the phylum
level, HFD mice had more Firmicutes (7361.5% vs 6862.3% for
controls; P=0.041) and fewer Bacteroidetes (1561.7% vs
1961.3% for controls; P=0.026) and thus a significantly higher
Firmicutes: Bacteroidetes ratio (P=0.019). HFD also induced
significant shifts in fecal microbiota composition at the genus level
of taxonomic resolution. Within members of the Firmicutes,
notably there was a 75% decrease in Lactobacillus (P,0.001) and a
279% increase in Oscillibacter (P=0.004) as compared to controls
and these changes in abundance were closely associated with
weight gain (Figure 4).
Transepithelial resistance of the proximal colon was positively
correlated with the abundance of Lactobacillus (r=0.52; P=0.013;
Figure 5A) but negatively correlated with that of Oscillibacter
(r=20.55; P=0.007; Figure 5B). Notably, increased Oscillibacter
abundance was also associated with a reduction in the mRNA
expression of ZO-1 (r=20.37; P=0.039; Figure 5C) and,
although not statistically significant, a similar trend was observed
with proglucagon (r=20.34; P=0.061; Figure 5D).
High saturated fat diet induced depot-specific
inflammation and altered morphology in adipose tissue
Representative immunohistochemical staining of the macro-
phage marker F4/80 in adipose tissue of control and HFD mice is
shown in Figure 6A. The abundance of macrophages (F4/80
+
cells) was similar across all fat depots in the control mice. HFD
increased macrophage infiltration in mesenteric (58%; P=0.020)
and epididymal (71%; P=0.006) fat but was without effect in
perirenal and subcutaneous fat (Figure 6B). HFD increased
adipocyte size in mesenteric (80%; P,0.001), epididymal (57%;
P=0.008), perirenal (104%; P=0.007) and subcutaneous (103%;
P=0.008) fat (Figure 6C). In both diet groups, mesenteric fat was
the depot with the smallest adipocytes (Figure 6C).
Compared to controls, HFD induced a 2.5-fold increase in the
mRNA levels of both TNF-a (P,0.001; Figure 7A) and IL-6
(P=0.008; Figure 7B) in the mesenteric fat. This depot had by far
the highest expression of TNF-a and IL-6 in mice fed the control
diet, with expression levels being very low, and unaffected by
HFD, in epididymal, perirenal and subcutaneous depots
(Figures 7A and B). HFD had no effect on the mRNA expression
of SREBP-1c and PPAR-c in adipose tissue. In both diet groups,
the highest expression of PPAR-c (P,0.001; Figure 7C) and
SREBP-1c (P=0.003; Figure 7D) were found in mesenteric and
epididymal fat respectively.
Figure 2. Effect of high saturated fat diet (HFD) on barrier
function of proximal colon. A: Transepithelial resistance of mouse
proximal colon was determined in the Ussing chamber by measuring
the change in potential difference in response to 3 mA current
generated across the tissue segment. B: mRNA levels of zona occludens
(ZO)-1 and proglucagon were measured using RT-qPCR. Gene
expression was normalized to RPL-19. Open circles/bars=control;
Closed circles/bars=HFD (n=9–16 per group). Data are shown as
mean 6 SEM. ***P,0.001 and *P,0.05 compared to control.
doi:10.1371/journal.pone.0034233.g002
Figure 3. Effect of high saturated fat diet (HFD) on markers of
inflammation in proximal colon. mRNA expression of indicated
genes was measured by RT-qPCR as described in Figure 2. Open
bars=control; Closed bars=HFD (n=11–16 per group). Data are shown
as mean 6 SEM. *P,0.05 compared to control.
doi:10.1371/journal.pone.0034233.g003
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lipogenic liver
As shown in Figure 8A, HFD-fed mice tended to have higher
expression of pro-inflammatory factors in the liver, as evidenced
by the increased TNF-a (6.5-fold; P=0.018) and IL-6 (2.2-fold;
P=0.137) mRNA expression. Hepatic SREBP-1c (6.4-fold;
P,0.001) and SCD1 (1.7-fold; P=0.069) mRNA levels were also
trended to be elevated in HFD mice (Figure 8B).
Discussion
The present study aimed to determine the effect of a high,
predominantly saturated, fat diet (HFD) on gut health and its
relationship with metabolic dysfunction. HFD mice exhibited
systemic inflammation, whole-body insulin resistance and liver
inflammation. We showed that HFD increased gut permeability
and altered gut microbiota profile. Importantly, we demonstrated
a relationship between gut barrier function and the abundance of
specific genera of the microbial community. Together with the
evidence of inflammation in the proximal colon and the distinct
pro-inflammatory nature of the contiguous mesenteric, but not
other fat depots, the present results highlight gut dysfunction as a
salient feature of diet-induced metabolic dysregulation.
Our data suggest that HFD initiates metabolic changes that
impaired gut barrier function, as evidenced both by the decrease
in transepithelial resistance and mRNA expression of ZO-1 in the
proximal colon. Similar outcomes for other obesogenic diets on
gut barrier function have also been reported. Cani et al [12]
showed an increase in whole-gut permeability in HFD mice, an
effect associated with a reduction in mRNA expression of tight-
junction proteins including ZO-1. Little is known, however, about
the barrier integrity of functionally distinct regions of the intestine
in diet-induced models of obesity. The present study focused
directly on the proximal colon, which is the part of the gut
predicted to have the most intense microbial activity. Accordingly,
loss of barrier integrity in the proximal colon has the potential to
induce a disproportionate effect of gut microbiota on systemic
metabolism.
The increased permeability of the proximal colon is postulated
to participate in a feedback loop with inflammatory processes. In
our study, and others using obesogenic diets, mice in the
experimental groups had increased TNF-a mRNA expression
[37] in the intestine. In an experimental model of colitis, the
progressive increase in colonic permeability is associated with a
corresponding reduction in ZO-1 protein expression [38]. There is
also some evidence suggesting a direct effect of TNF-a on gut
barrier integrity. Anti-TNF-a treatment improves gut barrier
function in patients with Crohn’s disease [39]. In Caco-2 cell
cultures, TNF-a reduced transepithelial resistance and ZO-1
protein expression via a NFkB-dependent pathway [40]. The
effect of TNF-a on NFkB activation also increased the expression
and activity of myosin light chain kinase, which subsequently leads
to disorganization of tight-junction proteins at the intestinal
barrier [41]. It is worth noting that other cytokines upstream of
NFkB, including IL-1b [42] and IFN-c [43], also have been shown
to decrease tight-junction function. The collective role of
inflammatory pathways, rather than individual cytokines, there-
fore, appears to be critical in the regulation of gut barrier function.
The activity of the microbiota is a major determinant of gut
health and a ‘poor’ microbiota composition has been linked to
Figure 4. Gut microbiota composition in control and high saturated fat diet (HFD) fed mice. A: Relative abundance of main genera in
fecal samples from control (open bars) and HFD (closed bars) mice (n=16 per group). Data are shown as mean 6 SEM. ***P,0.001, ** P,0.01 and
*P,0.05 compared to control. Correlations between the abundance of Lactobacillus (B) and Oscillibacter (C) and weight changes. Gut microbiota
profile was determined by metagenomic pyrosequencing from bacterial lineages in fecal samples.
doi:10.1371/journal.pone.0034233.g004
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Firmicutes and Bacteroidetes by obesogenic diets has been
frequently reported, but not universally so. Here we observed a
small, but significant shift towards an increased Firmicutes:
Bacteroidetes ratio in the HFD mice. The most startling
microbiota changes were observed within the Firmicutes, with a
very strong association between changes in relative abundance of
Lactobacillus and Oscillibacter and the two diet groups. Members of
the genus Lactobacillus have been intensively investigated for
probiotic properties and several strains have been shown to
ameliorate gut inflammation [45] and enhance barrier function
[46] in experimental models of gut dysfunction. A novel finding
here is the positive correlation between the abundance of the
indigenous Lactobacillus community (i.e. not administered probiotic
strains) and barrier function of the proximal colon. However we
did not observe a significant correlation between Lactobacillus
content and mRNA expression of tight-junction proteins. The
effect of probiotic Lactobacillus strains on tight-junction integrity is
not entirely clear and appears to be strain-specific [47,48]. In
humans, administration of L. plantarum promoted localization of
ZO-1 and occludin in the tight-junctions without necessarily
affecting their transcriptional levels [49]. It is worth noting that the
beneficial effect of Lactobacillus on gut health may not be restricted
to the maintenance of barrier integrity, as there is some evidence
suggesting that certain strains may alter the expression of defensin,
an anti-microbial peptide, which is important for mucosal
protection [50,51].
The present study identified Oscillibacter-like organisms as a
potentially important gut microbe that mediates HFD-induced gut
dysfunction. This group, including Oscillibacter and Oscillospira, are
very poorly represented in culture collections but have been
consistently detected in the microbial community of humans
[52,53]. Recent data suggest that the abundance of Oscillibacter is
diet-responsive in obese individuals [54] but to date little is known
about its physiological role. The negative correlation between the
abundance of Oscillibacter and parameters of barrier function in the
proximal colon is intriguing. There is some in vitro evidence
suggesting that metabolites from other gut microbes may modify
the abundance of certain strains of Oscillibacter [55]. It is possible
that Oscillibacter directly regulates components involved in the
maintenance of gut barrier integrity, or its relationship with gut
permeability may be a secondary effect consequent upon
alterations in the overall composition of the microbial community.
Characterization of the metabolic effect of Oscillibacter as well as its
interactions with other microbes would be critical to elucidate its
role in diet-induced metabolic dysfunctions.
We identified mesenteric fat as a metabolically distinct visceral
fat depot with the most prominent pro-inflammatory nature. Our
Figure 5. Correlations between Lactobacillus (A) and Oscillibacter (B–D) abundances and permeability parameters in proximal colon.
Gut microbiota profile was determined as described in Figure 4 (n=22–31). Transepithelial resistance and mRNA expression of zona occludens (ZO)-1
and proglucagon in proximal colon were measured as described in Figure 3.
doi:10.1371/journal.pone.0034233.g005
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34233Figure 6. Effect of high saturated fat diet (HFD) on adipose macrophage infiltration and adipocyte size. A: Representative
immunohistochemical staining of mesenteric (MES), epididymal (EPID), perirenal (PERI) and subcutaneous (SC) fat. Quantification of macrophage (F4/
80
+) infiltration (B) and adipocyte size (C). Tissues were fixed in formalin and embedded in paraffin. Sections were stained for F4/80 and
counterstained with hematoxylin. Open bars=control; Closed bars=HFD (n=4–10 per group). Data are shown as mean 6 SEM. ***P,0.001,
**P,0.01 and *P,0.05 compared to control.
doi:10.1371/journal.pone.0034233.g006
Figure 7. mRNA expression of TNF-a (A), IL-6 (B), PPAR-c (C) and SREBP-1c (D) in adipose tissue. mRNA levels in control and high
saturated fat diet (HFD) fed mice were measured by RT-qPCR. Gene expression was normalized to UBC. Open bars=control; Closed bars=HFD
(n=12–15 per group). Data are shown as mean 6 SEM. ***P,0.001 and **P,0.01 compared to control. a, b, c: P,0.001, P,0.01 and P,0.05
respectively compared to other depots in the same diet group.
doi:10.1371/journal.pone.0034233.g007
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of PPAR-c and the smallest adipocyte size. This is in contrast to
epididymal fat which had the biggest adipocytes and the highest
mRNA content of SREBP-1c, a transcription factor that promotes
lipogenesis. HFD mice had increased expression of TNF-a and IL-
6 and macrophage infiltration in mesenteric fat [13,56] and the
role of TNF-a in the systemic dysmetabolism may be particularly
critical [57]. Similar trends of depot-specific differences in the
expression of pro-inflammatory cytokines have been reported
previously in animal models of high-fat feeding [58,59].
A range of non-adipocytes cells are known to contribute strongly
to the pro-inflammatory secretory profile of adipose tissue [6].
Interestingly, the HFD-induced increase in macrophage infiltra-
tion was similar in mesenteric and epididymal fat, and yet only the
former had a distinctly elevated expression of pro-inflammatory
cytokines. A limitation of our study is that we used only F4/80 as a
macrophage marker, which did not allow us to distinguish sub-
populations of macrophages. The increased transcriptional
expression of pro-inflammatory factors in the mesenteric fat may
be a consequence of the preferential infiltration of macrophages
with a pro-inflammatory phenotype [60]. Equally, the presence of
lymph nodes in mesenteric [61], but not epididymal, fat implies
that immune cells other than macrophages, e.g. B-cells, T-cells
and Natural Killer cells, are likely to contribute to the secretory
function of the mesenteric depot.
The increased macrophage infiltration and TNF-a expression in
mesenteric fat of our HFD mice is consistent with results in rats
with induced gut inflammation [9] and is likely to be a
consequence of the ‘leakage’ of gut luminal content. Cenac et al
[62] demonstrated the sequential occurrences of gut inflammation,
impaired barrier function and bacterial translocation to the
mesenteric lymph nodes in an experimental model of colitis.
Similar metabolic sequelae of gut inflammation in obesity are yet
to be reported. However, the recent report of bacterial
translocation into the mesenteric fat of HFD mice [63] and of
elevated circulating endotoxin levels in animal models of diet-
induced obesity [12] and in obese and type 2 diabetic patients
related to insulin resistance [64,65] are consistent with our
hypothesized role of the gut in metabolic dysfunction [19].
Mechanistic studies will be an important extension of the
current work. We, and others, have shown that an obesogenic diet
can induce gut dysfunction involving multiple feedbacks with
immune and metabolic regulation. It remains unclear whether
HFD-induced gut dysfunction is a specific effect of fatty acid
subtype (e.g. saturated fatty acids are known to be pro-
inflammatory) or is merely a consequence of energy overload.
Elucidating the sequence of factors that initiates gut dysfunction
will be important for the maintenance of optimal metabolic health.
From the disease treatment perspective, the interactions and
feedback mechanisms between the innate immune system and the
microbiota profile and their effect on metabolic outcomes [18]
imply that a combination of pharmaceutical interventions of
immunomodulators (e.g. pro-resolving mediators that are critical
in maintaining immunological homeostasis of mucosal surface
[66]) and manipulation of microbiota (e.g. dietary supplementa-
tion of prebiotics, probiotics and resistant starches) may be novel
gut-targeted approaches to ameliorate metabolic dysfunctions.
In summary, the current findings build on a literature now
becoming compelling that the gut is a central player in the
aetiology of diet-induced metabolic diseases.
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Figure 8. mRNA expression of genes involved in inflammation
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